Introduction {#sec1_1}
============

Atherosclerosis is an inflammatory disease that affects medium and large arteries. Immune mechanisms underlie both the formation and activation of atherosclerotic plaques that cause ischemia from vessel stenosis or plaque rupture with thrombosis \[[@B1], [@B2]\]. The discovery of biomarkers that improve current methods of diagnosis and treatment of cerebral ischemia would be a valuable addition to patient care. Several categories of protein biomarkers that reflect brain tissue damage, inflammation, vascular injury, hemostasis or neuroendocrine responses have helped to delineate mechanisms and potential pathways for new therapies \[[@B3], [@B4], [@B5]\]. Similarly, microarray profiles of ribonucleic acid expression in blood can distinguish ischemic stroke from controls and other types of brain injury \[[@B6]\]. Single nucleotide polymorphisms of genes that regulate inflammatory pathways have been associated with an increased relative risk for ischemic stroke \[[@B7], [@B8], [@B9], [@B10]\]. However, due to the heterogeneity of causes of ischemic stroke and the lack of sufficient sensitivity and specificity, none of these markers are currently used routinely to assess risk, and diagnose, treat, or provide prognosis of cerebral ischemic events \[[@B3], [@B4], [@B5], [@B11]\].

Some of the biomarkers assessing risk associated with carotid artery disease are similar to those associated with cardiovascular risk, such as C-reactive protein or fibrinogen \[[@B12]\]. Blood levels of cholesterol and associated lipoproteins have a well-known relationship to the risk of coronary artery disease, yet this relation is only weakly associated in ischemic stroke suggesting possible differences in mechanisms or susceptibility of the different vascular beds to atherogenesis \[[@B13], [@B14], [@B15]\]. A recent systematic review of biomarkers associated with stroke risk and best therapy for carotid artery disease noted the heterogeneity of results from the studies of different biomarkers \[[@B12]\]. Clarifying the role of inflammatory markers that are predictive of carotid artery disease within a background of systemic atherosclerosis remains challenging.

In order to discover new protein biomarkers associated with increased atherosclerotic risk, we conducted a pilot study in patients with and without carotid artery disease. We hypothesized that patients with carotid artery disease would have a distinctive proteomic signature in blood as compared to a healthy control population. Our goal was to identify serological markers that would help distinguish patients with and without carotid atherosclerosis and those who were more likely to become symptomatic. We used two different strategies to identify biomarkers from patients with clinically defined atherosclerosis who were undergoing endarterectomy (EA) for carotid artery disease. We characterized the entire proteome in these patients by fractionating serum using anion exchange and then fractionating further using three different protein chip surfaces for screening with surface-enhanced laser desorption/ionization (SELDI)-time of flight (TOF) mass spectrometry (MS). A bioinformatic approach to establish multivariate classification models based on SELDI-MS data was used to distinguish the atherosclerosis group from the no atherosclerosis group. Samples from the symptomatic and asymptomatic EA group were analyzed using two-dimensional difference gel electrophoresis (2D-DIGE), matrix-assisted laser desorption/ionization (MALDI) tandem MS (MS/MS) and liquid chromatography MS/MS. Our results demonstrate both the utility and limitations of protein profiling using these approaches.

Materials and Methods {#sec1_2}
=====================

Sample Collection {#sec2_1}
-----------------

The atherosclerosis group was composed of 38 patients who had blood samples obtained prior to EA with carotid plaque removal. The control group consisted of 40 age-matched healthy subjects who were enriched for atherosclerotic risk factors but had no clinical evidence of atherosclerosis at the time of sampling. The atherosclerosis group was composed of both symptomatic (n = 16) and asymptomatic (n = 22) patients who underwent EA. The symptomatic patients underwent EA surgery after a prior stroke or transient ischemic attack (TIA) and met the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria for symptomatic atherosclerosis \[[@B16]\]. The asymptomatic atherosclerotic patients had no prior clinical sequelae from their vascular disease. Table [1](#T1){ref-type="table"} lists their baseline clinical characteristics. Serum from all patients who consented to participation was collected at the National Naval Medical Center under an institutional review board-approved protocol during outpatient visits prior to EA or in outpatient visits as appropriate. The serum was stored at −80°C before use. In symptomatic patients, samples were obtained within 1--4 weeks after TIA or stroke. The strokes were mild to moderate in severity.

Sample Fractionation {#sec2_2}
--------------------

Prior to generating protein expression profiles by SELDI analysis, serum samples were processed by anion exchange chromatography using a 96-well serum fractionation kit containing anion exchange resin according to the manufacturer\'s recommendations (Ciphergen Biosystems, Fremont, Calif., USA) and automated for high-throughput liquid handling on a Biomek 2000 automated workstation (Beckman Coulter, Fullerton, Calif., USA). Six total fractions with buffers of 50 m*M* Tris-HCl, 0.1% N-octyl-β-*D*-glucoside (OGP; pH 9; F1); 50 m*M* HEPES, 0.1% OGP (pH 7; F2); 100 m*M* Na acetate (pH 5; F3); 100 m*M* Na acetate, 0.1% OGP (pH 4; F4); 50 m*M* Na citrate, 0.1% OGP (pH 3; F5), and 33.3% isopropanol, 16.7% acetonitrile and 0.1% trifluoroacetic acid (TFA; organic, F6) were collected (fig. [1](#F1){ref-type="fig"}). Each of the six 200-μl fractions was then stored at −80°C until application to the ProteinChip arrays.

SELDI ProteinChip Analysis {#sec2_3}
--------------------------

Mass spectra from serum protein expression profiles were obtained using immobilized metal affinity capture (IMAC30), strong anion exchange (Q10) and/or weak cation exchange (CM10) ProteinChip arrays (Ciphergen Biosystems) and run in duplicate according the manufacturer\'s recommended protocols. All sample preparations, including deposition of matrix, were performed on a Biomek 2000 automated work station using two 96-well Bioprocessors from Ciphergen. For quality control purposes and to measure the chip-to-chip experimental variation, a pooled serum sample was prepared by mixing control and patient samples, and applied to 1 spot on each ProteinChip array used. The coefficients of variation (CV) of the intensity of each detectable peak were measured and the average variation across the entire range was \<25%. Spectra from each sample were generated using a high and low laser intensity reading in order to optimize the detection of both low and higher molecular weight proteins. Prior to all chip reading, the instrument performance was evaluated by measuring laser energy output, resolution and sensitivity, and then externally calibrated using standard calibrants spanning the user-defined range of the mass/charge ratio.

SELDI-MS Bioinformatic Analysis {#sec2_4}
-------------------------------

All SELDI-MS spectra were processed similarly using CiphergenExpress 2.1 data management software (Ciphergen Biosystems). Initially, both raw and processed data were analyzed. For spectrum-processing parameters, the general approach was the determination of the optimal baseline subtraction and smoothing algorithms, a total ion current normalization across all spectra, followed by a recalibration using peak alignment. A peak detection algorithm, using modifiable values for signal to noise and peak valley depth, was then employed to select peaks from a set of spectra from the same fraction and chip type. A Mann-Whitney U test was used to compare the mean intensity value of each recognized peak between two different clinical groups. The random forest (RF) program, which is a machine-learning classifier algorithm that makes group predictions based on many potentially correlated variables, was used to develop the multivariate classification models \[[@B17]\].

Albumin Depletion from Serum {#sec2_5}
----------------------------

Samples to be analyzed by 2D gels were albumin depleted using four Seppro Human Albumin IgY bead columns (Genway Biotech, San Diego, Calif., USA). Each serum sample was run through a column two times to obtain sufficient concentration of albumin-depleted serum proteins. Albumin-depleted and albumin-bound fractions were both recovered from the column and stored at −80°C. Symptomatic and asymptomatic samples were randomized with respect to columns. After all depletions, samples were thawed and a bicinchoninic acid assay (Pierce Biotechnology, Rockford, Ill., USA) was run to determine the protein concentration of the depleted and bound fractions for each sample. Samples were then stored at 4°C.

2D-DIGE and Image Analysis {#sec2_6}
--------------------------

Detailed protocols for sample preparation, fluorescent labeling, 2D-PAGE and image acquisition are presented in the online supplementary experimental protocol (for all online [suppl. material](#S1){ref-type="supplementary-material"}, see [www.karger.com/doi/10.1159/000334477](http://www.karger.com/doi/10.1159/000334477)). Briefly, after sample cleaning and denaturing, 25 μg of protein were used for the Cy2 standard pool. Albumin-depleted serum samples from symptomatic and asymptomatic EA patients were labeled using either Cy3 or Cy5 dye. The remaining non-labeled samples were pooled to create a physical average for a Coomassie-stained spot picking gel. Minimal labeling uses 50 μg of protein with 1 μl of 400 pmol DIGE dye. Amersham IPG Immobiline Drystrips (pH 3--10 NL, 24 cm) and 18 cm 4--12% gradient Precast gels (Jule, Milford, Conn., USA) were used for the 1st and 2nd dimensions. These gels were run using the Ettan DALT 12 system (Amersham Biosciences, Piscataway, N.J., USA). All gels were imaged using a Fuji Film FLA-5000 scanner and ImageView software. The picking gel was scanned using a laser wavelength at 473 nm with a long-pass blue filter. The image was saved as a 16-bit image with a resolution of 10 μm. DIGE gels were scanned twice using appropriate laser and filter settings for Cy3 and Cy5. The 2D-DIGE images were uploaded to [www.ludesi.com](http://www.ludesi.com) and analyzed for spot detection, segmentation and matching using the image analysis software, Ludesi 2D Interpreter.

Protein Identification {#sec2_7}
----------------------

*Tryptic in-Gel Digestion.* For 2D-DIGE experiments a picking gel for protein identification, was run simultaneously and stained with Coomassie blue. Protein spots of interest were excised from the gel and the gel plugs were digested with the trypsin profile IGD kit (Sigma, St. Louis, Mo., USA) or modified trypsin (Promega, Madison, Wisc., USA) according to the manufacturers' protocols. For protein identification using high-resolution MALDI-MS/MS, the digested sample was desalted with Vivapure C18 micro spin column or C18 ZipTip (Waters, Milford, Mass., USA) and eluted with 3 μl 60% ACN with 0.1% TFA.

High-resolution MALDI-TOF-TOF was acquired using an ABI 4700 proteomics analyzer (Applied Biosystems, Foster City, Calif., USA) operating in positive ion reflectron mode at 20 kV. The sample (0.5 μl) was mixed with 0.5 μl of the MALDI matrix (5 mg/ml of CHCA in 50% ACN and 0.1% TFA) and spotted onto the plate. The instrument was calibrated prior to analysis. The acquired spectra were submitted to MASCOT to search for matched proteins with human SPROT protein database.

Detailed experimental protocols are described in the online supplementary experimental protocols.

Results {#sec1_3}
=======

Patient Characteristics {#sec2_8}
-----------------------

Demographics and clinical characteristics of the patients with and without atherosclerosis are summarized in table [1](#T1){ref-type="table"}. Fifteen of 20 clinical variables were statistically different in the patients with atherosclerosis (e.g. coronary artery disease, peripheral vascular disease, angina, diabetes, hypertension and hypercholesterolemia). In contrast, comparisons of these clinical variables in patients with atherosclerosis who were symptomatic versus those who were asymptomatic prior to EA (table [2](#T2){ref-type="table"}) showed that other than the history of a previous ischemic event, none of the clinical variables were different between these two groups.

SELDI-MS Profiling {#sec2_9}
------------------

Univariate analysis of the SELDI data comparing the atherosclerosis patient group (n = 38) to non-atherosclerotic controls identified 42 peaks with p \< 0.01 by Mann-Whitney t tests of mean peak intensity (listed in online suppl. table [1](#S1){ref-type="supplementary-material"}). We utilized 3 different ProteinChip surfaces with different binding properties. The number of unique peaks will therefore be less as some of the proteins will bind to more than one SELDI surface resulting in an overlap of the peaks between chips.

In order to better classify the groups based on SELDI protein peak data, RF analysis was applied to the data set for an unbiased estimate of correct prediction rates \[[@B18]\]. The RF model demonstrated 69.2% sensitivity and 73.2% specificity in atherosclerosis prediction. The metric multidimensional scaling representation of the proximity matrix is shown in figure [2](#F2){ref-type="fig"}. Dimension (Dim) 1 and Dim 2 are approximations to the first two principal components of the similarity space defined by the model. Based on significance weighting of specific peaks in the RF models, the signal intensity of 4 unique SELDI peaks showed the greatest influence in distinguishing atherosclerosis samples from control patient samples (online suppl. fig. [2](#S1){ref-type="supplementary-material"}). SELDI-derived peaks had p \< 0.01 by univariate analysis. The 4 unique SELDI peaks were: 4.2 kDa (Q10, F6), 16.7 kDa (IMAC, F1), 4.4 kDa (CM10, F1) and 28 kDa (Q10, F5), with the chip type and anion-exchange fraction listed following the molecular mass of the peak. Based on our previous publication \[[@B19]\], the 28.1-kDa peak is apolipoprotein A~1~ (ApoA~1~). We did not attempt to further identify the 4.2-, 4.4- and 16.7-kDa peaks.

SELDI-MS Profiling of Symptomatic versus Asymptomatic EA Groups {#sec2_10}
---------------------------------------------------------------

We analyzed SELDI peak data to compare asymptomatic EA patients to symptomatic EA patients. RF analysis failed to develop models with high sensitivity and specificity. The balanced RF (average over 10 RF runs) yielded a sensitivity of 28.8% and a specificity of 52.7%.

2D-DIGE with Protein Identification of Differentially Expressed Proteins in the Symptomatic and Asymptomatic EA Groups {#sec2_11}
----------------------------------------------------------------------------------------------------------------------

2D-DIGE analysis of albumin-depleted serum on the 20 randomly selected samples revealed 11 spots with p \< 0.01 (fig. [3](#F3){ref-type="fig"}). Absolute spot intensity and volumes, p values and protein identification of these differentially expressed spots are shown in table [3](#T3){ref-type="table"}. Using MALDI-MS/MS and liquid chromatography MS/MS, 8 of the 11 proteins that were differentially expressed were identified (table [3](#T3){ref-type="table"}). Four of these spots were identified as belonging to the same parental protein molecule haptoglobin (HPT) and 2 were related to α~1~-antitrypsin (A~1~AT), both of which were downregulated in patients in the symptomatic EA group. It is likely that these spots represent proteins that are alternative splice variants or posttranslationally modified versions of the parental protein. Vitamin D binding protein (VTDB) was downregulated in the symptomatic EA, and leucine-rich α~2~-glycoprotein precursor (LRG) was upregulated in the symptomatic EA group (fig. [4](#F4){ref-type="fig"}).

Discussion {#sec1_4}
==========

Carotid atherosclerosis is one of the primary causes of ischemic stroke \[[@B20]\]. Endothelial activation due to inflammation at the site of the carotid plaque as well as systemic inflammation may contribute to thrombus formation \[[@B20], [@B21], [@B22]\]. Examination of carotid plaques removed from patients with ischemic strokes found that ulceration and thrombosis are more common in symptomatic patients \[[@B21]\]. Identifying proteins from the blood proteome that influence inflammation in patients with carotid atherosclerosis may provide some insight into the cause of thrombus formation and serve as potential biomarkers to identify patients at risk for developing symptomatic carotid atherosclerosis.

We hypothesized that differences in serum proteome expression between the atherosclerosis and control groups would be due to the presence of mature atherosclerotic plaques and not simply induced by the presence of atherosclerosis risk factors. We attempted to identify serological markers that would help us distinguish not only those patients with and without carotid atherosclerosis but also those who were more likely to become symptomatic. Using RF analysis of the entire protein spectra of fractionated serum from patients with and without carotid atherosclerosis revealed a 69.2% sensitivity and a 73.2% specificity in predicting the presence of atherosclerosis (table [1](#T1){ref-type="table"}; fig. [1](#F1){ref-type="fig"}). These results suggest that a distinctive pattern is present in patients with carotid atherosclerosis. The 4 peptide peaks showing the greatest effect in the RF analysis that discriminated between these groups had apparent molecular masses of 4.2, 4.4, 16.7 and 28 kDa. However, this approach did not discriminate between the patients with symptomatic versus asymptomatic carotid artery disease. This may reflect a limitation of the SELDI-TOF methodology as well as the smaller sample size of this subgroup analysis. The 28.1-kDa peak was reduced in patients with atherosclerosis and identified as ApoA~1~ based on a comparison of the signal characteristics to our SELDI database \[[@B19]\]. ApoA~1~ is a hepatic immediate-early response protein and a major component of high-density lipoprotein (HDL). It has antioxidant and anti-inflammatory actions and low HDL cholesterol and low ApoA~1~ levels have been found to be significant risk factors for all types of stroke \[[@B23], [@B24]\].

Using 2D-DIGE, we examined a subset of 20 patients with symptomatic or asymptomatic carotid atherosclerosis. Four proteins were differentially expressed and significantly different between these two subgroups and were identified as HPT, A~1~AT, VTDB and LRG. Two of these proteins, HPT and A~1~AT are part of a panel of acute-phase reactants termed inflammatory-sensitive plasma proteins (e.g. fibrinogen, A~1~AT, HPT, ceruloplasmin and orsomucoid) that have been shown in large cohort studies to be major risk factors for stroke \[[@B13]\]. Hypercholesterolemia in association with elevations in inflammatory-sensitive plasma proteins increases the risk of cardiovascular disease, ischemic stroke and myocardial infarction whereas in the absence of the proteins, no association was found between hypercholesterolemia and ischemic stroke \[[@B13]\]. These plasma biomarkers modify the risk of stroke in patients with hypercholesterolemia, hypertensive patients, and patients with obesity and diabetes \[[@B13], [@B18], [@B25]\]. A recent study showed similar findings using an inflammatory score based on white blood cell count, HPT and C-reactive protein that added predictive information above that of total cholesterol and triglycerides to predict major cardiovascular events (stroke, myocardial infarction or heart failure) in a healthy cohort over 1 decade \[[@B26]\].

HPT has several functions that may serve as a cofactor in symptomatic atherosclerotic disease. It is an acute-phase reactant that binds free hemoglobin, serves as an antioxidant and induces anti-inflammatory cytokines \[[@B27]\]. HPT also binds to ApoA~1~ on HDL, a site that is critical for lecithin cholesterolacyl transferase activity and may help bind hemoglobin to HDL making it a potentially proatherogenic molecule \[[@B27], [@B28]\]. A strong association of increased risk of micro- and macrovascular cardiovascular disease in patients with the Hp2:2 genotype and diabetes has been described \[[@B27]\]. Its role in non-diabetic cardiovascular disease remains to be defined \[[@B29]\].

VTDB is a major plasma carrier of vitamin D and its metabolites \[[@B30]\]. In addition, VTDB has other important functions, including scavenging actin, fatty acid transport, macrophage activation and enhancement of neutrophil and macrophage chemotaxis to C5 des Arg \[[@B30], [@B31]\]. Stressed endothelial cells release VTDB that has both a chemotactic function and serves as a growth factor for vascular smooth muscle cells \[[@B32]\]. Actin filaments released from damaged cells have the potential to damage the vasculature and enhance thrombosis \[[@B33]\]. Recently, VTDB has been found in both the serum and thrombotic plaques of patients with acute myocardial infarction \[[@B34]\]. VTDB administration in vitro decreased platelet aggregation and prolonged coagulation \[[@B34]\]. Further, patients with acute coronary syndromes have persistent elevation of plasma VTDB over 6 months compared to healthy volunteers \[[@B35]\]. We show that VTDB is present in patients with carotid artery atherosclerosis and that patients who were symptomatic prior to EA have lower levels of VTDB. Lower levels of VTDB in our symptomatic EA patients may have enhanced atherogenesis or contributed to an unstable atheromatous plaque.

LRG was elevated in symptomatic EA patients. It is an acute-phase reactant induced by proinflammatory cytokines, and increased expression has been found in several inflammatory conditions, including the sera of patients with graft-versus-host disease, lung and pancreatic cancer and in the cerebrospinal fluid of patients with normal pressure hydrocephalus \[[@B36]\]. LRG is upregulated during neutrophilic differentiation and is localized in azurophilic granules \[[@B37]\]. It binds to cytochrome c, a proinflammatory mediator, and is toxic to lymphocytes \[[@B36], [@B38]\]. The inflammation-modifying effects of LRG in the pathogenesis of atherosclerosis remain to be defined.

Multiple strategies are necessary to find new biomarkers associated with carotid atherosclerosis \[[@B39], [@B40]\]. Our study describes preliminary observations regarding biomarkers associated with symptomatic and asymptomatic carotid artery disease. Limitations of our study are based in part on its size and methodology. The SELDI platform is a semiquantitative tool for proteomic discovery and hypothesis generation. It provides spectral patterns that are rich with information, but limitations of this approach have been noted \[[@B39], [@B41]\]. In our patients, the timing of blood sampling after the acute event may have influenced our analysis. Some proteins may be upregulated during recovery from the acute event rather than representing a specific marker of carotid artery disease. Biomarkers measured in serum may not necessarily reflect biologic activity at the level of the plaque and may also be influenced by other factors, such as degradation in the serum, tissue metabolism and excretion. Lastly, our study did not control for the effects of different therapies (i.e. statins, cyclooxygenase inhibitors or antihypertensives) that may have unrecognized effects on the differentially expressed proteins. Our observations will require validation in other well-defined cohorts at risk for cerebral ischemia.

Supplementary Material
======================
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Click here for additional data file.
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![Four unique SELDI-MS peaks that showed the greatest influence in distinguishing atherosclerosis samples from patient samples with no evidence of atherosclerosis.](cee-0001-0115-g01){#F1}

![Multidimensional scaling representation of the proximity matrix for the RF analysis of atherosclerosis versus no atherosclerosis. Atherosclerosis samples are distinguished from no-atherosclerosis samples. Dim 1 and Dim 2 are approximations to the first two principal components of the similarity space defined by the model.](cee-0001-0115-g02){#F2}

![A representative 2D-DIGE image consisting of a single Cy5-labeled symptomatic EA patient serum, a Cy3-labeled asymptomatic EA patient serum and a Cy2-labeled internal standard control sample. The spots indicated with circles locate the position of the 11 differentially expressed spots with p \< 0.01.](cee-0001-0115-g03){#F3}

![Normalized fluorescent intensity values from each albumin-depleted sample of the three most statistically significant, differentially expressed spots observed by 2D-DIGE. The gray lines represent the mean from each group, while the red lines delineate standard deviations. Sample numbers are shown on the x-axis of each graph.](cee-0001-0115-g04){#F4}

###### 

Clinical characteristics of all patients

                         No clinical atherosclerosis (n = 40)   Atherosclerosis (n = 38)   p value
  ---------------------- -------------------------------------- -------------------------- ---------
  Males/females          32/8                                   31/7                       1.0
  Age, years             71.2 ± 8.3                             70.0 ± 9.5                 0.59
  Smoking                                                                                  
   Never                 25                                     11                         0.004
   Quit                  13                                     20                         0.45
   Active                2                                      7                          0.08
  Hypertension           17                                     36                         \<0.001
  High cholesterol       12                                     29                         0.003
  Diabetes               1                                      9                          0.023
  Atrial fibrillation    0                                      4                          0.05
  CAD                    0                                      16                         \<0.001
  CABG                   0                                      8                          0.002
  Angina                 0                                      8                          0.01
  MI                     0                                      6                          0.01
  PVD                    0                                      15                         \<0.001
  Claudication           0                                      13                         \<0.001
  Prior stroke or TIA    0                                      16                         \<0.001
  Glucose, mg/dl         92± 15                                 110± 47                    0.03
  Triglycerides, mg/dl   132± 58                                151± 93                    0.30
  Cholesterol, mg/dl     203± 30                                177± 34                    \<0.001
  HDL, mg/dl             58± 13                                 45± 11                     \<0.001
  LDL, mg/dl             123± 30                                103± 26                    0.003
  VLDL, mg/dl            26± 11                                 28± 11                     0.46
  WBC, 10^9^/1           5.92 ± 0.79                            7.32 ± 2.19                \<0.001
  Platelets, 10^9^/1     239± 64                                230± 57                    0.5
  Fibrinogen, mg/dl      358± 51                                382± 98                    0.19
  ESR, mm/h              11± 8                                  18± 16                     0.01
  C-reactive protein                                                                       
   \<1 mg/1              36                                     32                         0.51
   1--3 mg/1             1                                      5                          0.10
   \>3 mg/1              0                                      1                          0.48
   Not done              3                                      0                          

CAD = Coronary artery disease; CABG = coronary artery bypass graft; ESR = erythrocyte sedimentation rate; MI = myocardial infarction; PVD = peripheral vascular disease. Data are means ± SD. Comparisons of the groups (no clinical atherosclerosis vs. atherosclerosis) were done using either an unpaired t test or Fisher\'s exact test (InStat 3, version 3.0b, GraphPad Software) with nominal p values reported.

###### 

Clinical characteristics of the patients with atherosclerosis

                         Atherosclerosis   p value       
  ---------------------- ----------------- ------------- ---------
  Males/females          14/2              17/5          0.67
  Age, years             70.1 ± 12.3       70.0 ± 7.4    0.96
  Smoking                                                
   Never                 5                 6             0.49
   Quit                  9                 11            1.0
   Active                2                 5             0.67
  Hypertension           14                22            0.17
  High cholesterol       10                19            0.12
  Diabetes               5                 4             0.44
  Atrial fibrillation    1                 3             0.62
  CAD                    6                 10            0.74
  CABG                   2                 8             0.14
  Angina                 2                 6             0.42
  MI                     2                 4             1.0
  PVD                    5                 10            0.50
  Claudication           4                 9             0.48
  Prior stroke or TIA    16                0             \<0.001
  Glucose, mg/dl         101± 16           115± 60       0.37
  Triglycerides, mg/dl   132± 54           164± 115      0.31
  Cholesterol, mg/dl     171± 35           181± 33       0.36
  HDL, mg/dl             42± 10            46± 12        0.20
  LDL, mg/dl             103± 32           103± 20       0.93
  VLDL, mg/dl            27± 11            29± 12        0.66
  WBC, 10^9^/1           6.96 ± 1.77       7.58 ± 2.51   0.40
  Platelets, 10^9^/1     220± 67           237± 48       0.36
  Fibrinogen, mg/dl      382± 89           381± 108      0.99
  ESR, mm/h              16± 13            20± 18        0.47
  C-reactive protein                                     
   \<1 mg/1              14                18            1.0
   1--3 mg/1             2                 3             1.0
   \>3 mg/1              0                 1             1.0
   Not done              0                 0             

CAD = Coronary artery disease; CABG = coronary artery bypass graft; ESR = erythrocyte sedimentation rate; MI = myocardial infarction; PVD = peripheral vascular disease. Data are means ± SD. Comparisons of the two groups (symptomatic vs. asymptomatic atherosclerosis) were done using either an unpaired t test or Fisher\'s exact test (InStat 3, version 3.0b, GraphPad Software) with nominal p values reported.

###### 

Protein identification by MALDI-MS/MS and liquid chromatography-MS/MS for spots differentially expressed between symptomatic and asymptomatic EA patients using 2D-DIGE

  Spot No. (identifier)   Mean average spot volume ± SD   p value    Protein ID   MASCOT score   Peptides                                      
  ----------------------- ------------------------------- ---------- ------------ -------------- ---------- ---------------------------------- ----------------------------
  1(16,674)               1,092 ± 313                     767± 165   0.0039       HPT            141        GSFPWQAR                           
                                                                                                            VGYVSGWGR                          
                                                                                                            VTSIQDWVQK                         
                                                                                                            DIAPTLTLYVGK                       
                                                                                                            SCAVAEYGVYVK (C)                   
                                                                                                            YVMLPVADQDQCIR (C)                 
                                                                                                            YVMLPVADQDQCIR (C) (M)             
                                                                                                            SPVGVQPILNEHTFCAG (C) (M)          
                                                                                                                                               
  2(16,681)               780± 219                        535± 121   0.0029       HPT            82         YEELQITITAGR                       
                                                                                                            LALDLEIATYR                        
                                                                                                            WELLQQVDTSTR                       
                                                                                                            THNLEPYFESFINNLR                   
                                                                                  HPT            45         VGYVSGWGR YVMLPVADQDQCIR (C) (M)   
                                                                                                                                               
  3(16,682)               563 ± 68                        426± 82    0.0007       VTDB           84         YTFELSR                            
                                                                                                            THLPEVFLSK                         
                                                                                                            HLSLLTTLSNR                        
                                                                                                            EDFTSLSVLYSR                       
                                                                                                                                               
  4(16,723)               535 ± 87                        375± 66    0.0001       KAC            58         SGTASVVCLLNNFYPR (C)               
                                                                                                            TVAAPSVFIFPPSDEQLK                 
                                                                                  ADPGK          22         LAAAWDALIVRPVRR                    
                                                                                  PF21B          21         LASNYLNNPLFLTAR                    
                                                                                                            GSELQNEHQQLEEERDR                  
                                                                                                                                               
  5(16,770)               169 + 58                        317+106    0.0005       HPT            66         VGYVSGWGR                          
                                                                                                            VTSIQDWVQK                         
                                                                                                            YVMLPVADQDQCIR (C)                 
                                                                                                            YVMLPVADQDQCIR (C) (M)             
                                                                                                                                               
  6(17,006)               283± 74                         153± 42    0.0001       HPT            19                                            VGYVSGWGR
                                                                                                                                               YVMLPVADQDQCIR (C) (M)
                                                                                  OR2T6          13                                            AVMTSGGWR (M)
                                                                                  FHL1           11                                            VSHPVSKAR
                                                                                                                                               
  7(16,816)               128± 51                         293± 238   0.0028       MELT2          13                                            LSRLLKPGGMMLLR (M)
                                                                                  SUCB1          12                                            ALIADSGLKILACDDLDEA (C)
                                                                                  PCDG9          11                                            GRLVLLCSLLGMLWEAR (C)
                                                                                                                                               
  8(16,843)               103± 46                         240± 83    0.0015       LRG            35                                            DLLLPQPDLR
                                                                                                                                               TLDLGENQLETLPPDLLR
                                                                                                                                               
  10(16,862)              106± 27                         63± 38     0.0115       A~j~AT         116                                           FLENEDR
                                                                                                                                               WERPFEVK
                                                                                                                                               DTVFALVNYIFFK
                                                                                                                                               LQHLENELTHDIITHDIITK
                                                                                                                                               VFSNGADLSGVTEEAPLK
                                                                                                                                               DTEEEDFHVDQVTTVK
                                                                                                                                               TLNQPDSQLQLTTGNGLFLSEGLK
                                                                                                                                               
  11(16,868)              142± 48                         74± 36     0.0015       A~j~AT         134                                           FLENEDR
                                                                                                                                               WERPFEVK
                                                                                                                                               DTVFALVNYIFFK
                                                                                                                                               TDTSHHDQDHPTFNK
                                                                                                                                               LQHLENELTHDIITH
                                                                                                                                               VFSNGADLSGVTEEAPLK
                                                                                                                                               DTEEEDFHVDQVTTVK
                                                                                                                                               LYHSEAFTVNFGDTEEAK
                                                                                                                                               ELDRDTVFALVNYIFFK
                                                                                                                                               LYHSEAFTVNFGDTEEAKK
                                                                                                                                               GTEAAGAMFLEAIPMSIPPEVK (M)

Spot 9 was identified as keratin. (C) = Carbamidomethyl; (M) = oxidation.

[^1]: T.J.D.G., G.T.H. and P.N. contributed equally to the completion of this study.
